These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 28741113)

  • 21. [Anticoagulation of the extracorporeal circuit in chronic hemodialysis].
    Ryckelynck JP; Chouraqui D; Lobbedez T
    Nephrologie; 1998; 19(4):223-5. PubMed ID: 9675763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
    Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
    BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New developments in anticoagulants: Past, present and future.
    Weitz JI; Harenberg J
    Thromb Haemost; 2017 Jun; 117(7):1283-1288. PubMed ID: 28594426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin-induced thrombocytopenia in intensive care patients.
    Selleng K; Selleng S; Greinacher A
    Semin Thromb Hemost; 2008 Jul; 34(5):425-38. PubMed ID: 18956282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [-Anticoagulant drugs-].
    Gulba DC
    Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of direct oral anticoagulants: a practical approach.
    Shih AW; Crowther MA
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of specific antidotes as a response to bleeding complications during anticoagulant therapy for venous thromboembolism.
    Haverkamp D; Hutten BA; Büller HR; Gallus AS; Lensing AW; Prins MH
    J Thromb Haemost; 2003 Jan; 1(1):69-73. PubMed ID: 12871541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bleeding complications of unfractionated heparin.
    Krishnaswamy A; Lincoff AM; Cannon CP
    Expert Opin Drug Saf; 2011 Jan; 10(1):77-84. PubMed ID: 20868290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants.
    Shenoi RA; Kalathottukaren MT; Travers RJ; Lai BF; Creagh AL; Lange D; Yu K; Weinhart M; Chew BH; Du C; Brooks DE; Carter CJ; Morrissey JH; Haynes CA; Kizhakkedathu JN
    Sci Transl Med; 2014 Oct; 6(260):260ra150. PubMed ID: 25355700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticoagulation in patients with impaired renal function and with haemodialysis. Anticoagulant effects, efficacy, safety, therapeutic options.
    Harenberg J; Hentschel VA; Du S; Zolfaghari S; Krämer R; Weiss C; Krämer BK; Wehling M
    Hamostaseologie; 2015; 35(1):77-83. PubMed ID: 25405246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeutic approach to the bleeding in association with "old" and "new" anticoagulants].
    Dulíček P
    Vnitr Lek; 2012; 58(7-8):559-63. PubMed ID: 23067175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drugs for the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Am J Cardiovasc Drugs; 2001; 1(6):429-43. PubMed ID: 14728002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Reversal of Direct Oral Anticoagulants in Animal Models.
    Honickel M; Akman N; Grottke O
    Shock; 2017 Aug; 48(2):144-158. PubMed ID: 28471371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in anticoagulant drug delivery.
    Park J; Byun Y
    Expert Opin Drug Deliv; 2016; 13(3):421-34. PubMed ID: 26612251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly.
    Siguret V; Gouin-Thibault I; Gaussem P; Pautas E
    Drugs Aging; 2013 Sep; 30(9):687-99. PubMed ID: 23884865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Reversal for heparins and new anticoagulant treatments].
    Kortchinsky T; Vigué B; Samama CM
    Ann Fr Anesth Reanim; 2013 Jan; 32(1):37-49. PubMed ID: 23273505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study.
    Dyke CM; Smedira NG; Koster A; Aronson S; McCarthy HL; Kirshner R; Lincoff AM; Spiess BD
    J Thorac Cardiovasc Surg; 2006 Mar; 131(3):533-9. PubMed ID: 16515902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversing anticoagulants both old and new.
    Warkentin TE; Crowther MA
    Can J Anaesth; 2002; 49(6):S11-25. PubMed ID: 12557411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing Anticoagulation Management Through the Use of a Hospital Engagement Network Metric for Inpatient Anticoagulant-Associated Hemorrhage.
    Hoffman JL; Aneese NJ; Schmidt KJ; Chaben AC; Smythe MA
    Ann Pharmacother; 2015 Dec; 49(12):1305-10. PubMed ID: 26386409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.